title: Targeting the cancer kinome through polypharmacology.
abstract: Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit multiple kinases, how do we choose which ones? In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.
authors.affiliation: Zachary A. Knight is at The Rockefeller University, New York, New York 10065, USA.
authors.forename: Zachary A
authors.initials: ZA
authors.lastname: Knight
authors.forename: Henry
authors.initials: H
authors.lastname: Lin
authors.forename: Kevan M
authors.initials: KM
authors.lastname: Shokat
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016503:Drug Delivery Systems; D055808:Drug Discovery; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011494:Protein Kinases / Q000235:genetics; D034741:RNA, Small Interfering / Q000494:pharmacology; D013678:Technology, Pharmaceutical
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D034741:RNA, Small Interfering; D011494:Protein Kinases